Search Results

Viewing Page 1 of 1 | Showing Results 1 - 7 of 7

A PHASE 4, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC 10004) ON MRI OUTCOMES IN SUBJECTS WITH PSORIATIC ARTHRITIS

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable...

Philip Mease, MD
Seattle Rheumatology Associates
601 Broadway, Suite 600
Seattle, Washington 98122

Swedish Medical Center
747 Broadway
Seattle, Washington 98122

A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to...

Philip Mease, MD

Seattle Rheumatology Associates

Swedish Medical Center - First Hill

A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS DESPITE INITIAL STABLE TREATMENT WITH EITHER NSAIDS AND/OR ≤ 1 CONVENTIONAL SYNTHETIC DMARD.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 2 years of disease...

Phililp Mease, MD
Seattle Rheumatology Associates
601 Broadway, Suite 600
Seattle, Washington 98122

Swedish Medical Center
747 Broadway
Seattle, Washington 98122

A Phase 3, multicenter, randomized, double-blind, placebo controlled study evaluating the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to...

Philip Mease, MD

Seattle Rheumatology Associates

Swedish Medical Center - First Hill

A multicenter, phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo...

Philip Mease, MD

Seattle Rheumatology Associates

Swedish Medical Center - First Hill

A phase 3, multicenter, randomized, double-blind, placebo-controlled, active reference (adalimumab) study evaluating the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo...

Philip Mease, MD

Seattle Rheumatology Associates

Swedish Medical Center - First Hill

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to...

Philip Mease, MD

Seattle Rheumatology Associates

Swedish Medical Center- First Hill

Viewing Page 1 of 1 | Showing Results 1 - 7 of 7